ATE182080T1 - Dosierungsform die ein antigen und eine salzform eines organischen säurederivats eines sterols enthält - Google Patents

Dosierungsform die ein antigen und eine salzform eines organischen säurederivats eines sterols enthält

Info

Publication number: ATE182080T1
Authority: AT; Austria
Prior art keywords: antigen; sterol; organic acid; acid derivative; dosage form
Prior art date: 1988-08-25

Application number

AT94201844T

Other languages

English (en)

Inventor

Mircea C Popescu

Marie S Recine

Carl L Alving

Leonard F Estis

Lynn D Keyes

Andrew S Janoff

Original Assignee

Liposome Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-08-25

Filing date

1989-08-25

Publication date

1999-07-15

1989-08-25 Application filed by Liposome Co Inc filed Critical Liposome Co Inc

1999-07-15 Application granted granted Critical

1999-07-15 Publication of ATE182080T1 publication Critical patent/ATE182080T1/de

Links

239000000427 antigen Substances 0.000 title abstract 7
102000036639 antigens Human genes 0.000 title abstract 7
108091007433 antigens Proteins 0.000 title abstract 7
239000002552 dosage form Substances 0.000 title abstract 4
229930182558 Sterol Natural products 0.000 title abstract 3
150000007524 organic acids Chemical class 0.000 title abstract 3
150000003432 sterols Chemical class 0.000 title abstract 3
235000003702 sterols Nutrition 0.000 title abstract 3
150000003839 salts Chemical group 0.000 title abstract 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 4
230000003053 immunization Effects 0.000 abstract 4
238000002649 immunization Methods 0.000 abstract 3
239000002502 liposome Substances 0.000 abstract 3
235000012000 cholesterol Nutrition 0.000 abstract 2
230000028993 immune response Effects 0.000 abstract 2
206010022000 influenza Diseases 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
108010004032 Bromelains Proteins 0.000 abstract 1
101710154606 Hemagglutinin Proteins 0.000 abstract 1
101710093908 Outer capsid protein VP4 Proteins 0.000 abstract 1
101710135467 Outer capsid protein sigma-1 Proteins 0.000 abstract 1
239000004365 Protease Substances 0.000 abstract 1
101710176177 Protein A56 Proteins 0.000 abstract 1
229940024546 aluminum hydroxide gel Drugs 0.000 abstract 1
SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 abstract 1
235000019835 bromelain Nutrition 0.000 abstract 1
239000012634 fragment Substances 0.000 abstract 1
239000000185 hemagglutinin Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Immunology (AREA)
Mycology (AREA)
Virology (AREA)
Dispersion Chemistry (AREA)
Oncology (AREA)
Pulmonology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Manufacturing Of Micro-Capsules (AREA)

AT94201844T 1988-08-25 1989-08-25 Dosierungsform die ein antigen und eine salzform eines organischen säurederivats eines sterols enthält ATE182080T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US23670188A	1988-08-25	1988-08-25
US23670288A	1988-08-25	1988-08-25
US39777789A	1989-08-23	1989-08-23

Publications (1)

Publication Number	Publication Date
ATE182080T1 true ATE182080T1 (de)	1999-07-15

Family

ID=27398905

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT94201844T ATE182080T1 (de)	1988-08-25	1989-08-25	Dosierungsform die ein antigen und eine salzform eines organischen säurederivats eines sterols enthält
AT89402343T ATE119037T1 (de)	1988-08-25	1989-08-25	Influenzaimpfstoff und adjuvanten.

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AT89402343T ATE119037T1 (de)	1988-08-25	1989-08-25	Influenzaimpfstoff und adjuvanten.

Country Status (9)

Country	Link
EP (2)	EP0356339B1 (de)
JP (1)	JPH04500203A (de)
AT (2)	ATE182080T1 (de)
AU (2)	AU631377B2 (de)
CA (1)	CA1337332C (de)
DE (2)	DE68921389T2 (de)
ES (2)	ES2133477T3 (de)
GR (1)	GR3031244T3 (de)
NZ (2)	NZ241926A (de)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5985318A (en) *	1990-08-24	1999-11-16	Burroughs Wellcome Co.	Fusogenic liposomes that are free of active neuraminidase
GB9018690D0 (en) *	1990-08-24	1990-10-10	Wellcome Found	Vaccines
US5879685A (en) *	1991-05-08	1999-03-09	Schweiz, Serum- & Impfinstitut Bern	Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
CA2086831C (en) *	1991-05-08	1999-03-16	Reinhard Gluck	Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
AU5420494A (en) *	1992-11-02	1994-05-24	Yves Claude Nicolau	Method of reducing multidrug resistance in cells and tissues
CA2156525A1 (en) *	1993-02-19	1994-09-01	Susan Dillon	Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
DE69533693T2 (de) *	1994-02-24	2005-12-22	Novavax Inc.(n.d.Ges.d.Staates Delaware)	Impfstoffe, die paucilamelläre Lipidvesikel als Adjuvans enthalten
FR2726764B1 (fr) *	1994-11-14	1997-01-31	Pasteur Merieux Serums Vacc	Adjuvant pour composition vaccinale
US5919480A (en) *	1996-06-24	1999-07-06	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Liposomal influenza vaccine composition and method
HUE031886T2 (en)	2002-10-11	2017-08-28	Glaxosmithkline Biologicals Sa	Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
EP2172213B1 (de)	2003-01-30	2013-04-03	Novartis AG	Injizierbarer Impfstoff gegen multiple Meningokokken-Serogruppen
NZ546430A (en)	2003-10-02	2009-04-30	Novartis Vaccines & Diagnostic	Liquid vaccines for multiple meningococcal serogroups
GB0323103D0 (en)	2003-10-02	2003-11-05	Chiron Srl	De-acetylated saccharides
JP5600375B2 (ja)	2004-03-09	2014-10-01	ノバルティスバクシンズアンドダイアグノスティックス，インコーポレーテッド	インフルエンザウイルスワクチン
NZ550533A (en)	2004-04-30	2010-02-26	Novartis Vaccines & Diagnostic	Meningococcal conjugate vaccination comprising N. meningitidis and diphtheria toxin
GB0409745D0 (en)	2004-04-30	2004-06-09	Chiron Srl	Compositions including unconjugated carrier proteins
GB0500787D0 (en)	2005-01-14	2005-02-23	Chiron Srl	Integration of meningococcal conjugate vaccination
GB0410866D0 (en)	2004-05-14	2004-06-16	Chiron Srl	Haemophilius influenzae
EP2848692B1 (de)	2004-05-21	2017-08-16	Novartis Vaccines and Diagnostics, Inc.	Alphavirus-Vektoren für Influenzavirus-Impfstoffe
JP2008508320A (ja)	2004-07-29	2008-03-21	カイロンコーポレイション	Ｓｔｒｅｐｔｏｃｏｃｃｕｓａｇａｌａｃｔｉａｅのようなグラム陽性細菌に対する免疫原性組成物
GB0424092D0 (en)	2004-10-29	2004-12-01	Chiron Srl	Immunogenic bacterial vesicles with outer membrane proteins
GB0502095D0 (en)	2005-02-01	2005-03-09	Chiron Srl	Conjugation of streptococcal capsular saccharides
JP2008530245A (ja)	2005-02-18	2008-08-07	ノバルティスヴァクシンズアンドダイアグノスティクス，インコーポレイテッド	尿路病原性菌株由来の抗原
SI1858920T1 (sl)	2005-02-18	2016-07-29	Glaxosmithkline Biologicals S.A.	Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso
CA2626253A1 (en)	2005-10-18	2007-04-26	Novartis Vaccines And Diagnostics, Inc.	Mucosal and systemic immunizations with alphavirus replicon particles
CA2628152C (en)	2005-11-04	2016-02-02	Novartis Vaccines And Diagnostics S.R.L.	Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
ES2514316T3 (es)	2005-11-22	2014-10-28	Novartis Vaccines And Diagnostics, Inc.	Partículas similares a virus (VLPs) de Norovirus y Sapovirus
GB0524066D0 (en)	2005-11-25	2006-01-04	Chiron Srl	741 ii
PL2478916T3 (pl)	2006-01-27	2020-11-16	Seqirus UK Limited	Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy
US8063063B2 (en)	2006-03-23	2011-11-22	Novartis Ag	Immunopotentiating compounds
ES2536426T3 (es)	2006-03-23	2015-05-25	Novartis Ag	Compuestos de imidazoquinoxalina como inmunomoduladores
CN101448523A (zh)	2006-03-24	2009-06-03	诺华疫苗和诊断有限两合公司	无需冷藏储存流感疫苗
EP2382988A1 (de)	2006-03-31	2011-11-02	Novartis AG	Kombinierte mukosale und parenterale Immunisierung gegen HIV
PT2054431E (pt)	2006-06-09	2011-11-03	Novartis Ag	Confórmeros de adesinas bacterianas
WO2007144772A2 (en) *	2006-06-15	2007-12-21	Novartis Ag	Adjuvant-sparing multi-dose influenza vaccination regimen
GB0614460D0 (en)	2006-07-20	2006-08-30	Novartis Ag	Vaccines
EP2586790A3 (de)	2006-08-16	2013-08-14	Novartis AG	Immunogene von uropathogenen Escherichia coli
EP4585610A3 (de)	2006-09-11	2025-09-24	Seqirus UK Limited	Herstellung von influenzavirus-impfstoffen ohne verwendung von eiern
PT2121011E (pt)	2006-12-06	2014-07-31	Novartis Ag	Vacinas compreendendo um antigénio a partir de quatro estirpes do vírus da gripe
GB0700562D0 (en)	2007-01-11	2007-02-21	Novartis Vaccines & Diagnostic	Modified Saccharides
KR20100045437A (ko)	2007-06-27	2010-05-03	노파르티스 아게	첨가물이 적은 인플루엔자 백신
GB0713880D0 (en)	2007-07-17	2007-08-29	Novartis Ag	Conjugate purification
GB0714963D0 (en)	2007-08-01	2007-09-12	Novartis Ag	Compositions comprising antigens
KR101621837B1 (ko)	2007-09-12	2016-05-17	노파르티스 아게	Ｇａｓ57 돌연변이 항원 및 ｇａｓ57 항체
GB0810305D0 (en)	2008-06-05	2008-07-09	Novartis Ag	Influenza vaccination
GB0818453D0 (en)	2008-10-08	2008-11-12	Novartis Ag	Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
EP2537857B1 (de)	2007-12-21	2017-01-18	GlaxoSmithKline Biologicals SA	Mutante Formen von Streptolysin O
CN102356089B (zh)	2008-02-21	2014-02-19	诺华股份有限公司	脑膜炎球菌fHBP多肽
JP5518041B2 (ja)	2008-03-18	2014-06-11	ノバルティスアーゲー	インフルエンザウイルスワクチン抗原の調製における改良
CN103897045A (zh)	2009-01-12	2014-07-02	诺华股份有限公司	抗革兰氏阳性细菌疫苗中的Cna_B结构域
US8568732B2 (en)	2009-03-06	2013-10-29	Novartis Ag	Chlamydia antigens
EP3263128A3 (de)	2009-04-14	2018-01-24	GlaxoSmithKline Biologicals S.A.	Zusammensetzungen zur immunisierung gegen staphylococcus aureus
DK2442826T3 (en)	2009-06-15	2015-09-21	Univ Singapore	Influenza vaccine, composition and methods of using
US10988511B2 (en)	2009-07-07	2021-04-27	Glaxosmithkline Biologicals Sa	Conserved Escherichia bacterial IG-like domain (group 1) protein (ORF405) immunogens
CA2768186A1 (en)	2009-07-15	2011-01-20	Novartis Ag	Rsv f protein compositions and methods for making same
AU2010272243A1 (en)	2009-07-16	2012-03-08	Novartis Ag	Detoxified Escherichia coli immunogens
CN102596240B (zh)	2009-08-27	2015-02-04	诺华股份有限公司	包括脑膜炎球菌fHBP序列的杂交多肽
US20120237536A1 (en)	2009-09-10	2012-09-20	Novartis	Combination vaccines against respiratory tract diseases
GB0917002D0 (en)	2009-09-28	2009-11-11	Novartis Vaccines Inst For Global Health Srl	Improved shigella blebs
GB0917003D0 (en)	2009-09-28	2009-11-11	Novartis Vaccines Inst For Global Health Srl	Purification of bacterial vesicles
BR112012009014B8 (pt)	2009-09-30	2022-10-04	Novartis Ag	Processo para preparar conjugado de polissacarídeo capsular de s. aureus tipo 5 ou tipo 8 e molécula de transporte crm197, conjugado e composição imunogênica
CN102724988B (zh)	2009-09-30	2014-09-10	诺华股份有限公司	脑膜炎球菌fHBP多肽的表达
GB0918392D0 (en)	2009-10-20	2009-12-02	Novartis Ag	Diagnostic and therapeutic methods
CA2779816A1 (en)	2009-10-27	2011-05-05	Novartis Ag	Modified meningococcal fhbp polypeptides
GB0919690D0 (en)	2009-11-10	2009-12-23	Guy S And St Thomas S Nhs Foun	compositions for immunising against staphylococcus aureus
WO2011080595A2 (en)	2009-12-30	2011-07-07	Novartis Ag	Polysaccharide immunogens conjugated to e. coli carrier proteins
GB201003333D0 (en)	2010-02-26	2010-04-14	Novartis Ag	Immunogenic proteins and compositions
GB201005625D0 (en)	2010-04-01	2010-05-19	Novartis Ag	Immunogenic proteins and compositions
US9744228B2 (en)	2010-04-07	2017-08-29	Norvartis Ag	Method for generating a parvovirus B19 virus-like particle
EP2558069A1 (de)	2010-04-13	2013-02-20	Novartis AG	Benzonapthyridinzusammensetzungen und ihre verwendung
KR20130121699A (ko)	2010-05-28	2013-11-06	테트리스 온라인, 인코포레이티드	상호작용 혼성 비동기 컴퓨터 게임 기반구조
GB201009861D0 (en)	2010-06-11	2010-07-21	Novartis Ag	OMV vaccines
AU2011276328C1 (en)	2010-07-06	2016-01-21	Novartis Ag	Norovirus derived immunogenic compositions and methods
US9192661B2 (en)	2010-07-06	2015-11-24	Novartis Ag	Delivery of self-replicating RNA using biodegradable polymer particles
GB201101665D0 (en)	2011-01-31	2011-03-16	Novartis Ag	Immunogenic compositions
GB201017519D0 (en)	2010-10-15	2010-12-01	Novartis Vaccines Inst For Global Health S R L	Vaccines
CN102000332B (zh) *	2010-11-16	2012-07-04	南京农业大学	一种用于鸭禽流感口服黏膜免疫的复合佐剂
WO2012072769A1 (en)	2010-12-01	2012-06-07	Novartis Ag	Pneumococcal rrgb epitopes and clade combinations
CA2860331A1 (en)	2010-12-24	2012-06-28	Novartis Ag	Compounds
WO2012103361A1 (en)	2011-01-26	2012-08-02	Novartis Ag	Rsv immunization regimen
CA2835644C (en)	2011-05-13	2021-06-15	Novartis Ag	Pre-fusion rsv f antigens
CA2841047A1 (en)	2011-07-06	2013-01-10	Novartis Ag	Immunogenic compositions and uses thereof
EP2729165B1 (de)	2011-07-06	2017-11-08	GlaxoSmithKline Biologicals SA	Immunogene kombinationszusammensetzungen und ihre verwendung
EP2729178A1 (de)	2011-07-08	2014-05-14	Novartis AG	Tyrosinverbindungsverfahren
ES2687129T3 (es)	2011-07-25	2018-10-23	Glaxosmithkline Biologicals Sa	Composiciones y métodos para evaluar la inmunogenicidad funcional de vacunas contra parvovirus
GB201114923D0 (en)	2011-08-30	2011-10-12	Novartis Ag	Immunogenic proteins and compositions
EP2755994A2 (de)	2011-09-14	2014-07-23	Novartis AG	Impfstoffkombination gegen escherichia coli
US9358284B2 (en)	2011-09-14	2016-06-07	Glaxosmithkline Biologicals Sa	Methods for making saccharide-protein glycoconjugates
RU2636350C2 (ru)	2011-11-07	2017-11-22	Новартис Аг	МОЛЕКУЛА, СОДЕРЖАЩАЯ SPR0096 и SPR2021
WO2013084071A2 (en)	2011-12-08	2013-06-13	Novartis Ag	Clostridium difficile toxin-based vaccine
WO2013108272A2 (en)	2012-01-20	2013-07-25	International Centre For Genetic Engineering And Biotechnology	Blood stage malaria vaccine
WO2013124473A1 (en)	2012-02-24	2013-08-29	Novartis Ag	Pilus proteins and compositions
US10279026B2 (en)	2012-04-26	2019-05-07	Glaxosmithkline Biologicals Sa	Antigens and antigen combinations
RU2727476C2 (ru)	2012-04-26	2020-07-21	Новартис Аг	Антигены и антигенные композиции
RU2014151567A (ru)	2012-05-22	2016-07-10	Новартис Аг	Конъюгат менингококка серогруппы х
US20150140068A1 (en)	2012-07-06	2015-05-21	Novartis Ag	Immunogenic compositions and uses thereof
JP6283674B2 (ja)	2012-09-18	2018-02-21	グラクソスミスクラインバイオロジカルズソシエテアノニム	外膜小胞
TR201808684T4 (tr)	2012-10-02	2018-07-23	Glaxosmithkline Biologicals Sa	Lineer olmayan sakarit konjügatları.
RU2015106791A (ru)	2012-10-03	2016-11-20	Глэксосмитиклайн Байолоджикалз Са	Иммуногенные композиции
MX372810B (es) *	2013-10-02	2020-07-03	Univ Leland Stanford Junior	Composiciones de wnt y metodos para purificacion.
US10821175B2 (en)	2014-02-25	2020-11-03	Merck Sharp & Dohme Corp.	Lipid nanoparticle vaccine adjuvants and antigen delivery systems
CN104535017B (zh) *	2014-12-19	2017-11-21	合肥市百胜科技发展股份有限公司	在线轮廓测量装置
IL246378A0 (en) *	2016-06-21	2016-11-30	Technion Res & Dev Foundation	A hybrid matrix of polymers that adhere to the mucosa and a lipidic drug release system for the treatment of oral cancer
EP3528827A4 (de) *	2016-10-21	2020-11-04	Merck Sharp & Dohme Corp.	Influenza-hämagglutinin-protein-impfstoffe
WO2019145950A1 (en)	2018-01-23	2019-08-01	Technion Research & Development Foundation Limited	Collagenase loaded liposomes for enhancing drug delivery
EP3840770A1 (de)	2018-08-23	2021-06-30	GlaxoSmithKline Biologicals SA	Immunogene proteine und zusammensetzungen
WO2021169673A1 (en)	2020-02-26	2021-09-02	Versitech Limited	Pd-1-based vaccines against coronavirus infection
EP4333868A1 (de)	2021-05-04	2024-03-13	King Abdullah University Of Science And Technology	Immunogene zusammensetzungen von mutiertem sars-cov-2 n-protein und gen und verfahren zur verwendung davon
WO2023079528A1 (en)	2021-11-05	2023-05-11	King Abdullah University Of Science And Technology	Compositions suitable for use in a method for eliciting cross-protective immunity against coronaviruses
US20250302943A1 (en)	2021-11-05	2025-10-02	King Abdullah University Of Science And Technology	Re-focusing protein booster immunization compositions and methods of use thereof
WO2023178425A1 (en)	2022-03-23	2023-09-28	Nanovation Therapeutics Inc.	High sterol-containing lipid nanoparticles
WO2023184038A1 (en)	2022-04-01	2023-10-05	Nanovation Therapeutics Inc.	Mrna delivery method and composition thereof
CA3261556A1 (en)	2022-07-22	2024-01-25	Institut National de la Santé et de la Recherche Médicale	USE OF BORDETELLA STRAINS FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
EP4633671A1 (de)	2022-12-14	2025-10-22	Yale University	Zusammensetzungen und verfahren zur verwendung davon zur behandlung von virenbedingten krebs

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1502774A (en) *	1974-06-25	1978-03-01	Nat Res Dev	Immunological preparations
US4148876A (en) *	1975-09-29	1979-04-10	Burroughs Wellcome Co.	Biological preparations
US4201767A (en) *	1978-11-08	1980-05-06	Merck & Co., Inc.	Viral liposome particle
US4522811A (en) *	1982-07-08	1985-06-11	Syntex (U.S.A.) Inc.	Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4891208A (en) *	1985-04-10	1990-01-02	The Liposome Company, Inc.	Steroidal liposomes
US4721612A (en) *	1984-04-12	1988-01-26	The Liposome Company, Inc.	Steroidal liposomes
JPH0688911B2 (ja) *	1985-06-06	1994-11-09	国立予防衛生研究所長	インフルエンザワクチン及びその製造方法

1989
- 1989-08-24 AU AU42214/89A patent/AU631377B2/en not_active Ceased
- 1989-08-24 NZ NZ241926A patent/NZ241926A/xx unknown
- 1989-08-24 NZ NZ230423A patent/NZ230423A/en unknown
- 1989-08-24 AU AU41861/89A patent/AU627226B2/en not_active Ceased
- 1989-08-24 JP JP1509162A patent/JPH04500203A/ja active Pending
- 1989-08-25 DE DE68921389T patent/DE68921389T2/de not_active Expired - Fee Related
- 1989-08-25 CA CA000609464A patent/CA1337332C/en not_active Expired - Fee Related
- 1989-08-25 EP EP89402343A patent/EP0356339B1/de not_active Expired - Lifetime
- 1989-08-25 ES ES94201844T patent/ES2133477T3/es not_active Expired - Lifetime
- 1989-08-25 ES ES89402343T patent/ES2069600T3/es not_active Expired - Lifetime
- 1989-08-25 AT AT94201844T patent/ATE182080T1/de not_active IP Right Cessation
- 1989-08-25 AT AT89402343T patent/ATE119037T1/de not_active IP Right Cessation
- 1989-08-25 DE DE68929033T patent/DE68929033T2/de not_active Expired - Fee Related
- 1989-08-25 EP EP94201844A patent/EP0626169B1/de not_active Expired - Lifetime
1999
- 1999-09-16 GR GR990402336T patent/GR3031244T3/el unknown

Also Published As

Publication number	Publication date
EP0626169B1 (de)	1999-07-14
GR3031244T3 (en)	1999-12-31
DE68921389D1 (de)	1995-04-06
ES2133477T3 (es)	1999-09-16
JPH04500203A (ja)	1992-01-16
EP0356339A1 (de)	1990-02-28
EP0626169A2 (de)	1994-11-30
ATE119037T1 (de)	1995-03-15
AU631377B2 (en)	1992-11-26
DE68921389T2 (de)	1995-06-29
DE68929033T2 (de)	1999-12-30
AU4186189A (en)	1990-03-23
CA1337332C (en)	1995-10-17
EP0626169A3 (de)	1995-12-13
AU4221489A (en)	1990-03-23
EP0356339B1 (de)	1995-03-01
AU627226B2 (en)	1992-08-20
NZ230423A (en)	1993-08-26
DE68929033D1 (de)	1999-08-19
NZ241926A (en)	1993-08-26
ES2069600T3 (es)	1995-05-16

Legal Events

Date	Code	Title	Description
2006-05-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE68929033D1 (de)	1999-08-19	Dosierungsform die ein Antigen und eine Salzform eines organischen Säurederivats eines Sterols enthält
EP1180938A4 (de)	2005-03-16	Agentien, zusammensetzungen und verfahren zur diagnose und/oder behandlung oder vorbeugung von plaquebildenden erkrankungen
FI860015L (fi)	1986-01-02	Menetelmä rokotteen valmistamiseksi piluksia kantavien nisäkkään kudoksiin tarttuvien bakteerien aiheuttamia tauteja vastaan
ATE101340T1 (de)	1994-02-15	Neue arzneimittelformulierung sowie verfahren zu deren herstellung.
DE69332518D1 (de)	2003-01-09	Unterdrückung von autoimmunkrankheiten durch antigene in wartestellung
KR910700454A (ko)	1991-03-15	노인성 치매증(senile dementia) 치료용 조성물 및 치료방법
AU7752487A (en)	1988-01-29	Immunomodulating compositions and their use
FR2603107B1 (fr)	1992-04-24	Compositions, vaccin et anticorps monoclonaux utiles pour le traitement des affections par le virus hiv et procedes de production de ces anticorps et de diagnostic de la presence de ce virus
FI870808L (fi)	1987-02-25	9-alfa, 11-beta-substituerade och 11-beta-substituerade estraner.
PT89958A (pt)	1989-11-10	Processo de preparacao de antigenio k5 sulfatado e de fragmentos de antigenio k5 sulfatado, de isolamento de antigenio k5 e preparacao de composicoes farmaceuticas
AU1347688A (en)	1988-09-14	Viral antigen, process for its production, and application in diagnosis and therapy (vaccine)
NL189207C (nl)	1993-02-01	Flavivirus antigeen, werkwijze ter bereiding daarvan, tussenprodukten en werkwijze ter bereiding van een vaccin tegen japanse encefalitis.
FI913100A0 (fi)	1991-06-25	Farmaceutiska preparat.
FI874329A7 (fi)	1988-04-11	Menetelmä värittömän, hajultaan ja maultaan neutraalin kassia-siemenvalkuaisjauhon valmistamiseksi.
FI875015A0 (fi)	1987-11-13	Vaccin mot juverinflammation.
DE3685917D1 (de)	1992-08-13	Peptid-zusammensetzung fuer die herstellung von malaria-impfstoff, sowie fuer die vorbereitung von diagnostischen einzelteilen fuer den nachweis von malaria-aehnlichen krankheiten.
NO863460D0 (no)	1986-08-28	Fremgangsmaate til fremstilling av 6-fenoksymetyl-4-hydroksy-tetrahydropyran-2-on, fremgangsmaate til deres fremstilling, og deres anvendelse som legemiddel, farmasoeytiske preparater og mellomprodukter.
DK76191A (da)	1991-06-14	Filamentoest haemagglutinin fra b.pertussis
ATE244011T1 (de)	2003-07-15	Unterdrückung der thromboxanspiegel durch perkutane verabreichung von aspirin
FR2620333B1 (fr)	1990-01-05	Liposomes, leur procede de preparation et application desdits liposomes comme vecteur de produits
GB1212886A (en)	1970-11-18	Equine vaccine and vaccination treatment
US3097143A (en)	1963-07-09	Myristyl-gamma-picolinium chloride preserved polio vaccine and its production
SU556809A1 (ru)	1977-05-05	Способ получени антител к австралийскому антигену
SU1524226A1 (ru)	1996-05-27	Способ получения аллергена из пчелиного яда
NO910266D0 (no)	1991-01-23	Nye 6-methyl-19-nor-steroider, fremgangsmaate for fremstilling av disse, farmasoeytiske preparater inneholdende disse, og deres omdannelse til 17alfa-substituerte 19-nor-pregnadiener.